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Summary.-Many previous reports testify to the effectiveness of bleomycin as a
drug for the clinical treatment of squamous carcinomata, and some radiotherapists
have considered the possibility that an improved therapeutic ratio might be obtained
by combined treatment with bleomycin and radiation. This consideration has
been stimulated by recent reports ofthe effects ofcombined treatment withbleomycin
using mammalian cells in vitro. Experiments are described here in which a murine
squamous carcinoma has been used to obtain a survival curve for cells of tumours
treated in vivo with single doses of bleomycin alone or in combination with radiation
given before or after the drug. The survival curve for drug alone was a multi-
component curve with Do values of 0.1, 0-75 and2-7mg/kg. However,theresultsof
the experiments with combined treatment showed no evidence of potentiation.
BLEOMYCIN is an anti-tumour drug
discovered by Umezawa et al. (1966a, b).
Investigations have been made of its
actions on mammalian cells (Kunimoto,
Hori and Umezawa, 1967; Terasima,
Yasukawa and Umezawa, 1970; Terasima
and Umezawa, 1970). The drug has been
used clinically and has shown strong anti-
tumour activities against human tumours,
being specifically remarkably effective
against squamous carcinoma (Ichikawa,
1969; Miyake and Inuyama, 1971; Blum,
Carter and Agre, 1973). However, there
are no experimental data demonstrating
its effect on squamous carcinoma.
Recently, Matsuzawa et al. (1972) sug-
gested that bleomycin had a potentiating
effect when used in combination with
radiation.
The purpose of the present work was
to determine the dose survival relation-
ship with a murine epithelioma, whose
response to bleomycin has not yet been
studied, and to ascertain whether or not
bleomycin interacts with radiation in our
tumour system as it appears to do in vitro.
MATERIALS AND METHODS
Mlice.-Male or female mice of strain
WHT/Ht were used as tumour hosts in the
TD50 experiments.
Tumour.-This was a transplantable kera-
tinizing squamous carcinoma which arose
spontaneously in a WHT/Ht mouse and has
since been maintained by serial passage
subcutaneously. A full description of the
tumour has been reported by Hewitt, Chan
and Blake (1967) and Hewitt and Sakamoto
(1971).
Treatment with bleomycin.-The stock
solution of bleomycin was prepared at a
concentration of 5 0 mg/ml in saline from
powder as is used clinically. For use, the
stock solution was diluted with saline
to give a range of concentration of the drug
from 0 03 mg/ml to 2-0 mg/ml, in order to
keep the volume of 0 3 ml as a constant
volume, to be injected intraperitoneally with
changes in drug dose.
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Irradiation. X-rays were geneiated by a
therapy machine operated at 180 kVp and
20 mA and were filtered through 0 7 mm Cu
and 0-5 mm A]. The exposure rate, measured
with a Victoreen condenser chamber (Model
570) without any additional absorber, using
the calibration factor supplied by the
Electro Technical Laboratories, Tokyo, was
78 rad/min; the FSD w%as 35 cm. Single
unanaesthetized tumour bearing mite were
exposed to whole body irradiation while
confined in a perforated Perspex cylinder,
immediately before or at 1 h after bleo-
mycin treatment.
Survival of tumour cells. Tumour bearing
mice were prepared by the subcutaneous
injection of 80,000 tumour cells into each
axilla 10-11 days before treatment; the
tumour at this stage weighed 1-5-2-0 g. The
mice were treated intraperitoneally with a
range of doses of bleomycin 1 h before
killing. Single-cell suspensions of tumours
cells were prepared from the tumours by a
method described previously (Hewitt, 1966).
Transplantation assays of counted suspen-
sions were performed by the technique
described by Hewitt et al. (1967). The TD50
(number of cells required for successful
transplantation to half a group of injected
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sites) and its 95% confidence limits were
calculated from the results of an assay by
the method of Litchfield and Wilcoxon
(1949). A series of assays of cells from
untreated tumours yielded ameanTD50 of9-6
cells. The surviving fraction of cells from
treated tumours was therefore obtained from
the expression 9.6/TD50 for treated cells.
RESULTS
Survival oftumour cells treated by bleomycin
The single-dose survival curves of the
squamous carcinoma cells exposed to
bleomycin are shown in Fig. 1 and 2.
The curve in Fig. 1 has 2 components,
the first part bending at a dose level of
approximately 0-2 mg/kg. The Do of the
first component is 041 mg/kg and that of
the second part is 0 75 mg/kg. The
single-dose survival curve of the tumour
cells treated at higher dose levels of
bleomycin, shown in Fig. 2, demonstrates
a third component. (The first com-
ponent in Fig. 2 corresponds to the second
component in Fig. 1.) In Fig. 2 the
second component shifts to the third
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FIG. 1. Survival of clonogenic squamous carcinoma cells 1 h after treatment with 0-1-1 5 mg/kg
bleomycin.
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FIG. 2.-Survival of clonogenic squamous carcinoma cells 1 h after treatment with 15-l100 mg/kg
bleomycin.
component at a dose level of 2-5 mg/kg,
the Do of the third component being
2-7 mg/kg.
The explanation for the trimodal
response to the drug, indicated by the
shape of the survival curve, is not clear
but will be considered further in the
Discussion.
Survival oftumour cells treated by combined
bleomycin and radiation
Figures 3 and 4 show the survival of
squamous carcinoma cells given combined
treatment with bleomycin and x-rays.
In Fig. 3 the open circles indicate the
survival of tumour cells exposed to
graded doses ofx-rays 1 h after treatment
with 03 mg/kg of bleomycin; the closed
circles show the survival of tumour cells
treated with 03 mg/kg of bleomycin for
1 h immediately after exposure to graded
doses of x-rays. Figure 4 shows the
results of similar experiments to those
in Fig. 3, except that 1 0 mg/kg ofbleomy-
cin was given instead of 0 3 mg/kg (as
in the experiments shown in Fig. 3).
In Fig. 3 and 4 the solid lines are super-
imposed from previously published data
(Sakamoto and Sakka, 1973a), these being
the survival curveforsquamous carcinoma
cells irradiated in air under the same
irradiation conditions as used in this
paper. The interrupted lines show the
expected tumour cell survivals if bleo-
mycin has only an additive cell killing
effect when combined with x-rays. It is
clear from the results shown that bleomy-
cin has no potentiating effect with radia-
tion in the killing of squamous carcinoma
cells.
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FiG. 3.-Survival of tumour cells after combined treatment with bleomycin and x-rays. 0, survival
of cells exposed to x-rays I h after treatment with 0 3 mg/kg bleomycin. 0, survival of cells
treated for 1 h with 0 3 mg/kg bleomycin immediately after exposure to graded doses of x-rays.
Solid line is superimposed from previously published data (Sakamoto and Sakka, 1973a).
Iinterrupted line shows the expected tumour cell survivals if bleomycin has only an additive cell
killing effect with x-rays.
DISCUTSSION
The compound survival curve obtained
for bleomycin shows some resemblance
to that commonly obtained for cells of
solid tumours irradiated in vivo (Powers
and Tolmach, 1963; Clifton, Briggs and
Stone, 1966; Reinhold, 1966), in which
the cell population exposed consists of a
mixture of oxygenated and hypoxic cells
ofwidely different radiosensitivities. The
bleomycin dose survival curve also
resembles the survival curve for epithe-
lioma cells exposed to neocarzinostatin
(Sakamoto and Sakka, 1973b), except for
the third component in the survival curve
for bleomycin. In the case ofthe survival
curve for bleomycin, its shape is open
to several possible interpretations: (1)
hypoxic cells may be more resistant to the
drug, as they are to irradiation; (2) the cell
population may consist of 3 components
differing in sensitivity to the drug on
account of some feature other than their
oxygenation; (3) the more resistant cells
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Fie-. 4. Survival of tumour cells after combine(d treat,ment with bleomycin an(l x-rays. 0, survival
ofcells oftumours exposed to x-rays I h after treatment with 1-0 mg/kg bleomycin. 0, survival
of cells treated for 1 h with 1-0 mg/kg bleomycin imme(liately after exposure to gradedl doses
of x-rays.
Solid line and interrupted line are the same as in Fig. 3.
niay be those less accessible to the drug
because of vascular deficiency; (4) there
may be a limiting concentration of drug,
above which there is no enhancement of
cytolethality, additional drug being
wasted ".
Matsuzawa et al. (1972) suggest that
bleomycin potentiates the effect of x-rays
using mouse cancer cells in vitro; Bien-
kowska, Dawson and Peacock (1973)
showed no interaction between bleomycin
and x-rays using HeLa cells. In ouir
experimental system, bleomycin shows
no potentiating effect with x-rays. In
the experiment using combined treatment,
we administered x-ray doses over 1000rad,
but recently it has become clear that there
is no potentiating effect even with a dose
of less than 1000 rad.
Bleomycin has been reported to have
a remarkable effect on clinical squamous
carcinomata; it was also found to be as
effective in the present experimental
system as neocarzinostatin given in doses
10 times as large (Sakamoto and Sakka,
1973b). However, the results reported
s~~~~~
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here do not suggest that a potentiating
effect between bleomycin and radiation
can be expected.
This investigation was supported in
part by the Wacksman's Foundation of
Japan.
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